RCEL logo

AVITA MEDICAL INC

RCELNASDAQ
πŸ† #3001 by market capEarnings Nov 5 Β· PostUS Equity
$16.71β–² $0.21 (+1.27%)
πŸŒ™ After hours$16.29β–Ό 2.52%Regular close Β· extended-hours price shown
πŸ””
Track RCEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.3%
7dβ–² 7.6%
14dβ–² 28.1%
30dβ–² 42.1%
ytdβ–² 384.3%
1yβ–² 357.8%
🏦Market Cap
$415M
Small Cap
πŸ“ˆRevenue Growth (YoY)
11.4%
Healthy
πŸ“ŠGross Margin
81.6%
High
πŸ’΅FCF Margin
-31.2%
Thin
βš–οΈP/S Ratio
5.5x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$16.40 – $16.90
52-Week Range
$3.22 – $16.90
Volume (shares)
312,014
Avg Volume (shares)
β€”
Shares Outstanding
24.8M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$72M
Last Q Revenue
$22M
P/E Ratio
-11.5
P/S Ratio
5.5x
EPS (TTM)
$-1.40
Dividend Yield
0.00%
Dilution (1yr)
+16.2%
RCEL logo

AVITA MEDICAL INC

RCEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$72Mβ–² +11.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
82.1%β–Ό βˆ’4.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$43Mβ–Ό βˆ’24.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$33Mβ–Ό βˆ’43.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.4Mβ–² +16.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36Mβ–Ό βˆ’$4M YoY
StockOtter Β· stockotter.space

About AVITA MEDICAL INC

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cmΒ²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy3
Buy5
Hold1
Sell0
Strong Sell1
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWireΒ·9d ago

AVITA Medical to Announce Third Quarter 2026 Financial Results

VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (β€œAVITA Medical,” or the β€œCompany”), a leading therapeutic acute wound care company delivering transformative solutions, to

Defense WorldΒ·17d ago

Head-To-Head Comparison: Organigram Global (NASDAQ:OGI) versus Avita Medical (NASDAQ:RCEL)

Organigram Global (NASDAQ: OGI - Get Free Report) and Avita Medical (NASDAQ: RCEL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the

Seeking AlphaΒ·18d ago

Leading Indicators For The October Breakout Cycle

Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of

GuruFocusΒ·27d ago

Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued

On October 02, 2026, AVITA Medical Inc (RCEL) shares rose 5.9% to a current price of $12.72, within a 52-week range of $3.22 to $12.76. The stock has shown impr

Defense WorldΒ·Sep 25

NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL

NewEdge Advisors LLC grew its position in Avita Medical Inc. (NASDAQ: RCEL) by 71.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 148,931 shares of the co

Seeking AlphaΒ·Sep 16

AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript